Kronos Bio Stock

kronosbio.comHealthcareFounded: 2017Funding to Date: $123MM

Kronos Bio is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription.

Register for Details

For more details on financing and valuation for Kronos Bio, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Kronos Bio.

Register Today

Team

Management Team

Philip Gutry
Chief Business Officer
Jorge Dimartino Ph.D
Chief Medical Officer & Executive Vice President
Christopher Wilfong
Chief Operating Officer & Co-Founder
Angela Koehler Ph.D
Scientific Founder
Norbert Bischofberger Ph.D
Chief Executive Officer, President & Board Member

Board Members

Arie Belldegrun MD
Vida Ventures (Boston)
John Martin Ph.D
Rebecka Belldegrun MD
Bellco Capital
Joshua Kazam
Two River Group
David Tanen
Two River Group
Otello Stampacchia Ph.D
Omega Fund
Norbert Bischofberger Ph.D
Jakob Loven Ph.D
Nextech Invest

Other companies like Kronos Bio in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
 
 
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$1.59B
Sector
 
 

News

Kronos Bio has raised $105 million in financing to develop therapies intended to target disease-causing proteins that have so far eluded the best efforts